A shared genetic signature for common chronic pain conditions and its impact on biopsychosocial traits

Scott F. Farrell PhD[1,2,3], Pik-Fang Kho PhD[4,5,6], Adrián I. Campos PhD[7], Miguel E. Rentería PhD[8], Rutger M. J. de Zoete PhD[9], Michele Sterling PhD[1,2], Trung Thanh Ngo PhD[1,10†] & Gabriel Cuéllar-Partida PhD[10†*]

Author affiliations:

1. RECOVER Injury Research Centre, The University of Queensland, Herston QLD, Australia

2. NHMRC Centre of Research Excellence: Better Health Outcomes for Compensable Injury, The University of Queensland, Herston QLD, Australia

3. Tess Cramond Pain & Research Centre, Royal Brisbane & Women's Hospital, Herston QLD, Australia

4. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford CA, USA

5. Molecular Cancer Epidemiology Laboratory, Department of Genetics & Computational Biology, QIMR Berghofer Medical Research Institute, Herston QLD, Australia

6. School of Biomedical Sciences, Queensland University of Technology, Brisbane QLD, Australia

7. Institute for Molecular Bioscience, The University of Queensland, St Lucia QLD, Australia

8. Genetic Epidemiology Laboratory, Department of Genetics & Computational Biology, QIMR Berghofer Medical Research Institute, Herston QLD, Australia

9. School of Allied Health Science and Practice, The University of Adelaide, Adelaide SA, Australia

10. Diamantina Institute, The University of Queensland & Translational Research Institute, Woolloongabba QLD, Australia

[†] These authors contributed equally to this work

[*] Current address: 23andMe Inc., Sunnyvale CA, United States of America

Correspondence to:

Dr Scott Farrell

RECOVER Injury Research Centre — Surgical, Treatment & Rehabilitation Service (STARS | Level 7), 296 Herston Rd, Herston QLD 4029, Australia.

E: Scott.Farrell@uq.edu.au | P: +61 7 334 64791 | F: +61 7 334 69136

Dr Trung Ngo

RECOVER Injury Research Centre — Surgical, Treatment & Rehabilitation Service (STARS | Level 7), 296 Herston Rd, Herston QLD 4029, Australia.

E: Trung.Ngo@uq.edu.au | P: +61 42 111 7258

Running Title: Biopsychosocial genetic signature of chronic pain

Abstract

***Background*:** The multifactorial heterogenous nature of chronic pain with its multiple comorbidities presents a formidable challenge in disentangling the aetiology underlying patient symptoms.

***Methods*:** Here, we performed genome-wide association studies (GWAS) of eight regional chronic pain types using UK Biobank data (N=4,037–79,089 cases; N=239,125 controls), followed by bivariate linkage disequilibrium-score regression and latent causal variable analyses to determine (respectively) their genetic correlations and genetic causal proportion (GCP) parameters with 1,492 other complex traits.

***Findings*:** We report evidence of a shared genetic signature across several common chronic pain types as their genetic correlations and causal directions were broadly consistent across a wide array of biopsychosocial traits. Furthermore, we identified 5,942 significant genetic correlations, of which 570 trait pairs showed evidence of a causal association (|GCP| > 0.6; 5% false discovery rate), including 488 traits contributing to chronic pain while 82 were affected by pain. A range of somatic pathologies (e.g., musculoskeletal, visceral), psychiatric traits (e.g., depression, trauma, anxiety, mania, bipolar disorder), socioeconomic factors (e.g., occupation) and other medical comorbidities (e.g., cardiovascular disease) contributed to an increased risk of regional chronic pain. Conversely, each chronic pain type contributed to various other traits such as increased medication use (e.g., analgesics) and increased risk of ischaemic heart disease & depression.

***Interpretation*:** This data-driven study — through comprehensive analysis of the many conflicting factors in chronic pain — has delineated a common genetic basis and underlying genetic causal relationships. Furthermore, it demonstrates a novel & efficient strategy for sharpening the prevailing biopsychosocial model of chronic pain disorders — such as enhancing the design of

interventional trials targeting identified underlying causal factors — to help accelerate the development of more effective treatments with broader clinical utility.

***Funding*:** Australian Government Research Training Program Scholarship.

Research in Context Panel

Evidence before this study

Previous work examining the genetic bases of chronic pain conditions and associated traits including candidate gene, twin and genome-wide association studies (GWAS) have been limited in scope and scale — based on PubMed, MedRxiv & BioRxiv searches (from inception to 16 March 2022) using the terms “pain” and “genetic” with no language restrictions. Therefore, a comprehensive delineation of genetic causal direction across several common chronic pain conditions and biopsychosocial traits would address a major evidence gap in rheumatology, pain & rehabilitation medicine and many allied fields.

Added value of this study

By leveraging UK Biobank and several other large-scale GWAS datasets including >1400 biopsychosocial factors, we provide evidence for a shared genetic signature across common chronic pain types. This novel finding suggests an increased genetic risk in developing multiple chronic pain types. This study also provides genetic evidence with >5900 significant genetic correlations to support phenotypic associations widely observed in previous clinical pain studies. Furthermore, it has characterised the multidimensional casual traits by narrowing down a range of genetically supported risk and protective factors for chronic pain, which lays the foundation for translational studies to identify causal genetic variants and pathophysiological pathways for developing novel diagnostic & therapeutic strategies.

Implications of all the available evidence

A shared genetic signature across chronic pain conditions supports a universal/conserved core upon which to focus interventions for more durable therapeutic effectiveness and broader clinical utility, alongside genetically stratified patient subtyping strategies. For instance, the precedent for genetically supported therapeutic (drug) targets & mechanisms suggests further interrogation of the complex traits identified in our study — through interventional trials targeting such causal factors — may help to accelerate the clinical validation of novel effective treatments for common chronic pain conditions.

Introduction

Despite enormous research efforts into determining the aetiology of chronic pain, common musculoskeletal conditions such as back pain and neck pain remain a major clinical and scientific challenge. Over the past decade however, large-scale genome-wide association studies (GWAS) have made inroads towards elucidating the biological pathways and complex traits contributing to a wide range of conditions such as neurological, psychiatric and cardiometabolic disorders.[1] While such studies have provided evidence for genetically supported therapeutic targets and mechanisms,[2,3] the application of statistical genetics methods to rheumatological[4-7] and chronic pain conditions[8-10] as a strategy towards disentangling their causal mechanisms requires further comprehensive and concerted effort.

Previous clinical and epidemiological studies have found a range of psychiatric, lifestyle and socioeconomic factors associated with an increased risk of chronic pain,[11] while medical conditions such as obesity and cardiovascular diseases are also common comorbidities.[11] Large-scale GWAS have identified specific genetic loci in chronic pain conditions (e.g., back pain[9] & widespread pain[10]) and demonstrated shared genetic bases with biopsychosocial traits (e.g., depression[9,10,12]). However, the nature of causal relationships between common chronic pain conditions and such multidimensional factors remains to be comprehensively examined.

Here we investigated the genetic correlations & causal relationships between eight types of regional chronic pain and a comprehensive range of biological, psychological/psychiatric and social traits. In the largest phenome-wide study of chronic pain to date, we leveraged GWAS summary statistics in the Complex Traits Genetics Virtual Lab (CTG-VL — http://genoma.io)[13]

to delineate the putative genetic causal directions across common chronic pain conditions and >1,400 other traits/disorders.

Methods

Discovery GWAS Datasets for Chronic Pain

An overview of the analysis pipeline employed in the present study is shown in Figure 1. We performed GWAS of regional chronic pain types using the UK Biobank resource (application number 25331). The UK Biobank holds research ethics approval from the North West Multi-centre Research Ethics Committee (Manchester, United Kingdom). All participants provided written informed consent.

Chronic pain was defined using self-report answers to the following questions: *Have you had [back pains / neck or shoulder pains / hip pains / knee pains / abdominal pains / facial pains / headaches / pain all over the body] for more than 3 months?* (Questionnaire field ID: 6159). These questions could be answered with *Yes*, *No*, *Don't know*, or *Prefer not to answer*. Participants who responded *Yes* to a question were defined as cases for that specific chronic pain type (i.e., chronic back pain, chronic widespread pain [pain all over the body] etc.). We defined controls as participants who denied experiencing any pain for more than three months (N=239,125). Participants who preferred not to answer were excluded from the study. Sample sizes of each GWAS were as follows: back pain (N=79,089); neck/shoulder pain (N=72,216); hip pain (N=41,677); knee pain (N=77,996); abdominal pain (N=21,285); facial pain (N=4,037); headache (N=39,283); widespread pain (N=6,063). Sample characteristics are further detailed in Supplementary Table S1.

We performed GWAS using REGENIE (v1·0·6·2)[14] to test associations between the chronic pain types and genetic variants. REGENIE is a GWAS method that implements a logistic mixed model, whereby a genetic relationship between individuals is modelled as a random effect to account for cryptic relatedness. Covariates for the association analysis comprised sex, age, genotyping array and the top 10 principal components derived from genetic data. We used quality control procedures comprising exclusion of variants with: **(i)** minor allele frequency (MAF) < 0·005; **(ii)** imputation quality < 0·6; and **(iii)** deviation from Hardy-Weinberg equilibrium (P-value < 1×10^{-5}). Subsequently, 11,172,285 single nucleotide polymorphisms (SNPs) remained for analysis. Participant data were excluded if their genotype-derived principal components 1 and 2 were more than six standard deviations from those of the 1000 Genomes European population. Following quality control, up to 441,088 participants remained in the GWAS.

Genetic Correlations

Genetic correlations were estimated between the regional chronic pain types and a wide range of other complex traits. Cross-trait bivariate linkage disequilibrium (LD) score regression was used — a method that leverages the expected relationship between LD and GWAS association statistics to estimate genetic correlations across traits while accounting for potential sample overlap across studies,[15] as implemented in CTG-VL.[13] CTG-VL is a publicly available web platform compiled with >1,490 GWAS summary statistics that is used for running analyses across a comprehensive range of complex traits & disorders (mostly from UK Biobank releases). CTG-VIEW (https://view.genoma.io) is a data aggregator that enables direct queries, visualisations and storage of VL analysis results (and that from other data resources).

A genetic correlation (*rG*) ranges from -1 to 1 and quantifies the genome-wide genetic concordance between a pair of traits. Genetic correlation estimates approaching 1 or -1 indicate (respectively) that a proportion of genetic variants have concordant or divergent effects on both traits. Conversely, a genetic correlation that approaches 0 indicates there is little genetic concordance between the traits or that the genetic predictors of the traits are largely independent. A Benjamini-Hochberg false discovery rate (FDR < 5%) procedure was applied to genetic correlations between complex traits and each chronic pain type GWAS to account for multiple testing.

Latent Causal Variable Analyses

For trait pairs with non-zero genetic correlation (FDR < 5%), we employed latent causal variable (LCV) analyses to determine if the genetic correlation reflected a causal relationship or horizontal pleiotropy by estimating genetic causal proportion (GCP).[16,17] The LCV method is robust to horizontal pleiotropy, which is ubiquitous in complex traits. LCV analyses can be conceptualised as assuming a latent 'causal' variable that mediates the genetic correlation of two traits. Using mixed fourth moments of the bivariate effect size distribution across all SNPs in both GWAS, LCV estimates the posterior mean for GCP, which indicates the degree to which one trait is correlated with the latent 'causal' variable. GCP estimates range from -1 to 1: high positive values (GCP > 0·6) indicate greater partial genetic causality for Trait A (i.e., a chronic pain type) on Trait B (i.e., biological / psychological / social trait); whereas negative values (GCP < -0·6) indicate greater partial genetic causality for Trait B on Trait A. That is, GCP > 0·6 indicates that chronic pain likely has a causal effect on another particular trait, whereas GCP < -0·6 indicates a particular trait likely has a causal effect on chronic pain. Benjamini-Hochberg false discovery rate (FDR < 5%) was applied across GCPs for complex traits with each chronic pain type GWAS.

Role of the Funding Source

The study funding sources had no role in study design; collection, analysis, and interpretation of data; writing the report; and decision to submit the paper for publication.

Results

Genetic Correlations & Latent Causal Variable Analyses

For each of the eight chronic pain types, details of significant genetic correlations with putative causal relationships are summarised in Figures 2–8 and Supplementary Figures S1 & S2, while *rG* and GCP data are reported in Supplementary Tables S2–S9. Complete genetic correlation and LCV analysis results for all 1,492 traits are presented in Supplementary Tables S10–S17.

From 11,932 trait pairs, we identified 5,942 significant genetic correlations (which corroborate many reported phenotypic associations from previous clinical studies), of which 570 trait pairs showed evidence of a causal association (|GCP| > 0·6; 5% false discovery rate). Of these, 488 traits had genetic casual effects on chronic pain, while the remaining 82 traits were affected by pain.

Comparisons of *rG* and significant GCP results across the eight chronic pain types are presented in Figures 2 & 3. Overall, the direction of the genetic correlations between the complex traits and chronic pain were broadly consistent across all eight types. There were eight instances where the direction of genetic causal relationships (denoted by GCP > 0·6 or < -0·6) differed between the chronic pain types (Supplementary Table S18). Additional *rG* estimates for the eight chronic pain

types are presented in Supplementary Table S19, including significant genetic correlations between each type, whereby the analysis method accounted for the overlapping samples.

Key Results Across Chronic Pain Types

Significant *rG* (5% FDR) and GCP estimates (< -0·6; 5% FDR) were observed for musculoskeletal pathologies, which showed genetic causal effects on chronic back, neck/shoulder, hip, knee, abdominal, headaches and widespread pain, including local sites (e.g., coxarthrosis of the hip & chronic hip pain *rG* [S.E.] = 0·42 [0·06]; GCP [S.E.] = -0·90 [0·08]) as well as remote sites (e.g., other intervertebral disc disorders & chronic knee pain *rG* [S.E.] = 0·61 [0·12], GCP [S.E.] = -0·79 [0·16]) (Figures 4–8, Supplementary Figures S1 & S2, Supplementary Tables S2–S9). Cardiovascular disease-associated traits affected each of the chronic pain types (e.g., heart failure contributes to back pain [*rG* (S.E.) = 0·22 (0·09); GCP (S.E.) = -0·73 (0·16)] and hip pain [*rG* (S.E.) = 0·30 (0·11); GCP (S.E.) = -0·62 (0·24)]), while certain chronic pain types (i.e., neck/shoulder, abdominal, facial & widespread pain) also affected cardiovascular traits such as ischaemic heart disease (neck/shoulder pain *rG* [S.E.] = 0·30 [0·04], GCP [S.E.] = 0·71 [0·22]; facial pain *rG* [S.E.] = 0·26 [0·09], GCP [S.E.] = 0·64 [0·22]). A number of chronic pain types (i.e., back, neck/shoulder, hip, knee, abdominal & headaches) contributed to medication use for cholesterol, blood pressure, diabetes or exogenous hormones. Chronic headaches and widespread pain also impacted the use of analgesics (i.e., paracetamol, ibuprofen, aspirin; and paracetamol, respectively), while the use of various medications (e.g., analgesics, cardiovascular drugs) affected chronic back, neck/shoulder, hip, knee, abdominal, headache and widespread pain.

Psychological traits and psychiatric diagnoses also had genetic causal effects on chronic pain types. Notably: **(i)** depression and anxiety-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, abdominal, headache and widespread pain; **(ii)** mania-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, facial and widespread pain; and **(iii)** substance abuse/addiction-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, abdominal, facial and widespread pain. Traits concerning bipolar disorder and psychosis respectively increased the risk of hip, knee and widespread pain; and of neck/shoulder, knee and facial pain. Chronic back pain, facial pain and headaches had genetic causal effects upon traits concerning depression, anxiety and mania (significant *rG* [5% FDR] and GCP > 0·6 [5% FDR]). Traits specific to occupations demonstrated genetic causal contributions to back, neck/shoulder, hip, knee, abdominal and widespread pain (e.g., receptionist & chronic back pain *rG* [S.E.] = 0·38 [0·17]; GCP [S.E.] = -0·97 [0·04]), while traits relating to work environment increased the risk of all eight chronic pain types (e.g., *'Workplace had a lot of diesel exhaust: Often'* and chronic widespread pain *rG* [S.E.] = 0·60 [0·15]; GCP [S.E.] = -0·81 [0·15]).

Region Specific Summaries

Additional results on the key findings for each pain type are presented in the Supplementary Results.

Discussion

The multifactorial and dynamic nature of chronic pain conditions means that assessing aetiological relationships is particularly challenging due to the large sample sizes and long follow-up

timeframes required for multivariate longitudinal analyses. Large-scale genetic datasets adequately powered for GWAS along with statistical genetics methods developed for investigating causality (e.g., LCV, Mendelian randomization [MR]) present a way forward. The primary findings of this data-driven study provide quantitative genetic evidence for a range of shared biopsychosocial factors demonstrating causal effects upon eight common types of chronic pain. Certain clinical factors (e.g., musculoskeletal pathology, medical comorbidities), psychological/psychiatric traits (e.g., depression, trauma, anxiety, mania) and socioeconomic factors (e.g., occupation) increased the risk of chronic pain types. The results also indicated genetic causal effects of chronic pain upon other traits such as increased medication use and an increased risk of cardiovascular disease and depression. The current study has characterised the multidimensional casual traits and substantially narrowed down the range of genetically supported risk and protective factors for chronic pain. This work lays the foundation for further translational studies to identify the underlying causal genetic variants and pathophysiological pathways for developing novel diagnostic and therapeutic strategies and technologies[7].

Overall, the directions of genetic correlations were consistent across an array of biopsychosocial traits and common chronic pain types. The vast majority of significant genetic causal directions between them were also consistent, while only a small minority differed across the chronic pain types — which suggests an underlying universal genetic core that is shared with these complex traits. In addition, significant genetic correlations found between each of the eight chronic pain types provides further evidence of a shared genetic signature, which builds upon recent studies[4,18] and earlier proposals[19] pursuing this otherwise elusive empirical demonstration. Moreover, the biopsychosocial traits identified in our study represent candidates for patient classification, risk

stratification and pain phenotyping in the clinical management of chronic pain conditions.[6] Based on the precedent for genetically supported therapeutic targets,[2,3] the identified traits with genetic causal effects also represent potential targets in the clinical management of chronic pain, as our results provide corroborating genetic evidence for current treatment and prevention strategies (e.g., respectively, weight-loss in knee osteoarthritis[20] & targeting post-traumatic stress after injury[21,22]).

Our results provide corroborating genetic evidence that musculoskeletal pathologies (e.g., intervertebral disc disorders in back pain, spondylopathies in neck/shoulder pain, coxarthrosis in hip pain) and visceral pathologies (e.g., renal & ureteric calculi) contribute to chronic pain. We also found genetic causal effects of painful pathologies at remote sites upon regional chronic pain types (e.g., shoulder impingement on chronic hip pain), which is consistent with a shared genetic signature and associated predisposition to chronic pain (i.e., an underlying genetic predisposition to musculoskeletal shoulder pathology also contributes to increased risk of chronic hip pain). Similarly, facial pain demonstrated genetic evidence of contributing to nerve-related pathologies (including mononeuropathies & carpal tunnel syndrome), which may reflect genetic mechanisms in common between trigeminal neuralgia and other neuropathic pain conditions.

Not surprisingly, our results indicate that certain chronic pain types (i.e., headaches & widespread pain) contribute to the use of analgesic medications (i.e., paracetamol, ibuprofen, aspirin; and paracetamol, respectively). Interestingly, various drugs used in the treatment of pain (e.g., opioids, non-steroidal anti-inflammatory drugs, antidepressants[12]), cardiovascular disease (e.g., statins, beta-blockers) and gastro-oesophageal reflux showed an effect of increased risk for various chronic pain types. While some of these may reflect a genetic correlation between pain and

problematic opioid use,[23] the effect of medication use on increasing the risk of chronic pain may also be attributable to an indirect causal effect. For example, an unobserved trait (e.g., symptom or disease), which increases the likelihood of both medication use and a chronic pain type, could create an apparent casual effect between that medication and the pain type. That is, medication use (e.g., analgesics) could simply serve as a proxy for conditions that cause pain or that are commonly co-morbid with chronic pain. For instance, statins and beta-blockers may serve as proxies for cardiovascular disease, while antidepressants may reflect the relationship between chronic pain and depression,[12] or conversely, the use of antidepressants to treat chronic pain conditions.[24,25]

Our findings indicate that while pain conditions and psychological traits (e.g., depression) are frequently co-morbid at a phenotypic level, the pattern of causal relationships between them are heterogenous across the various chronic pain types. For instance, we observed genetic evidence of causal relationships across both directions between depression-associated traits and chronic headaches & back pain (i.e., a proportion of relationships are pain → depression and others are depression → pain [Supplementary Tables S2, S8]). In contrast, depression-associated traits exclusively showed effects on chronic neck/shoulder, hip, knee, abdominal and widespread pain (i.e., depression → pain only [Supplementary Tables S3–6, S9]), consistent with evidence for (modest) effects of treatments targeting depression upon pain & disability in such conditions (e.g., serotonin-noradrenaline reuptake inhibitors for knee osteoarthritis[25]). Conversely, chronic facial pain increased the risk of seeking care for depression (i.e., pain → depression only [Supplementary Table S7]). These findings are broadly consistent with other genetic studies of complex traits concerning depression and chronic pain, which have shown: **(i)** genetic correlations between depression-related traits and various pain conditions[9,26]; and **(ii)** genetic causal relationships

between chronic pain and depression, spanning both depression → pain pathways[26] and pain → depression pathways.[10,26] Taken together, the current study's results and previous findings[10,12,26] raise further intriguing hypotheses, such as either or both causal directions may exist on a patient sub-group basis,[24] which may even change over time as their condition/comorbidities further develop. Our LCV results also implicate a history of trauma or stress — including the death of a close relative in last two years; being adopted as a child; sexual assault; marital separation; and military service — as genetic causal factors for various chronic pain types. Phenotypic studies have previously reported that trauma or post-traumatic stress are risk factors for the development of chronic pain.[27] Our LCV results provide independent convergent evidence for targeting post-traumatic stress symptoms in the treatment of pain, such as recently reported in a randomised controlled trial of whiplash-associated disorder,[21] which showed reductions in pain & disability through improvements in stress, depression & post-traumatic stress.[22] In addition to depression and trauma, traits concerning anxiety, psychosis, bipolar disorder and mania showed genetic causal effects on several chronic pain types. Socioeconomic factors (particularly concerning occupation) also demonstrated genetic causal effects on a range of chronic pain types and are discussed further in the Supplementary Results. Broadly, traits associated with lower socioeconomic status had a genetic causal impact of increased chronic pain risk, which suggests that interventions and policies targeting socioeconomic inequality may have beneficial downstream effects on the community burden of chronic pain.

Various medical conditions such as cardiovascular, gastrointestinal, respiratory and haematological diagnoses demonstrated genetic correlations and genetic causal relationships with chronic pain types. Notably, cardiovascular-related traits showed heterogeneous associations. For

example, heart failure contributed to chronic back and hip pain, whereas neck/shoulder and facial pain increased the risk of ischaemic heart disease. Numerous cardiovascular risk factors showed genetic causal contributions to chronic pain such as obesity (i.e., hip, knee & widespread pain), low-density lipoprotein/Apolipoprotein B (i.e., back, neck/shoulder, hip & knee pain) and triglycerides (i.e., facial & widespread pain). These findings are consistent with phenotypic correlations between chronic pain and cardiovascular diagnoses & mortality, which may reflect other associations between chronic pain and cardiac risk factors (e.g., smoking).[11]

Strengths, Limitations & Further Research

The present study employed LCV analyses to delineate traits with evidence of genetic causal contributions across eight chronic pain types. From a total pool of >11,900 trait pairs, it was distilled down to <5% with the vast majority (488/570) showing genetic causal effects on chronic pain. This analytical strategy employing large-scale comprehensive data and statistical genetics methods for investigating causality has characterised a broad range of genetically supported risk and protective factors for common chronic pain types.

A limitation of the current study is the minimal clinical details used to define regional chronic pain, i.e., a self-report questionnaire regarding presence of pain for >3 months at a body site. However, this minimal phenotyping approach enables acquisition of large-scale data with sufficient power for GWAS and post-GWAS analyses of causal relationships. As the chronic pain and complex trait GWAS data were mostly derived from the UK Biobank, we employed LCV analyses rather than a more traditional approach (e.g., MR) because overlapping samples in the latter can bias estimates towards the confounded associations.[28] Although the LCV method is not

able to detect bidirectional relationships between two individual traits (e.g., chronic pain → Trait A and Trait A → chronic pain), its current data-driven application in comprehensive phenome-wide analyses — particularly for complex chronic disorders such as persistent pain — is an efficient & effective strategy upon which to follow up with traditional approaches (e.g., MR, genomic structural equation modelling[29]) targeting the genetic causal traits delineated in the current study.

Further work is required such as: **(i)** genetic epidemiology studies collecting data on more specific chronic pain diagnoses, clinical traits (e.g., pro- & anti-nociceptive phenotypes, medication/treatment responses[24]) and epigenetic factors (e.g., early life stress, physical activity); **(ii)** replication in other large genotyped datasets[4,9] and particularly population samples with non-European ancestry; and **(iii)** incorporating putative transdiagnostic subtypes and genetic risk stratification of placebo/control groups in randomised clinical trials of chronic pain interventions.[2,3,12,24,30]

Conclusion

Our LCV analysis of >1,400 biopsychosocial complex traits has leveraged the underlying genetic variant data to provide a comprehensive characterisation of the risk and protective factors across common regional chronic pain conditions, and in turn, testable hypotheses for further targeted interrogation. It has also provided corroborating genetic evidence for current treatment approaches (e.g., targeting psychological traits), which lays the foundation for further translational studies into developing more effective multidisciplinary care frameworks and enhancing patient outcomes.

Data Sharing Statement

Complex trait GWAS summary statistics are publicly available. Links to reference and download each of these are available in CTG-VL (https://vl.genoma.io) and CTG-VIEW (https://view.genoma.io). Complete GWAS summary statistics and results from downstream analyses for all the chronic pain types reported in the current study (Supplementary Table S1) are available at CTG-VIEW.

Funding

AIC was supported by a UQ Research Training Scholarship from The University of Queensland. PFK was supported by an Australian Government Research Training Program Scholarship from Queensland University of Technology (QUT). RECOVER Injury Research Centre (MS, SFF) receives unrestricted grant funding from the Motor Accident Insurance Commission (Queensland). The funders had no role in the design or interpretation of this study. This research was initially carried out at the Translational Research Institute (TRI), Woolloongabba, QLD 4102, Australia. TRI is supported by a grant from the Australian Government. SFF, TTN & GC-P conceived the study. TTN & GC-P co-supervised the study. SFF & TTN performed the literature search. AIC & MER performed the GWAS. SFF performed downstream analyses with support from GC-P. SFF prepared the figures with support from TTN & GC-P. All authors contributed to interpretation of results. SFF, TTN & GC-P wrote the manuscript with feedback from all coauthors.

Declaration of Interests

GC-P contributed to this study while employed at The University of Queensland. He is now an employee of 23andMe, Inc and may hold stock in the company.

References

1. Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. *Nature Reviews Genetics* 2021; **22**(10): 658-71.

2. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. *PLOS Genet* 2019; **15**(12): e1008489.

3. Ginsburg GS, Cavallari LH, Chakraborty H, et al. Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. *Genetics Med* 2021; **23**(7): 1185-91.

4. Boer CG, Hatzikotoulas K, Southam L, et al. Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations. *Cell* 2021; **184**(18): 4784-818.e17.

5. Vincent TL. Of mice and men: converging on a common molecular understanding of osteoarthritis. *Lancet Rheumatol* 2020; **2**(10): e633-e45.

6. Nijs J, George SZ, Clauw DJ, et al. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. *The Lancet Rheumatology* 2021; **3**(5): e383-e92.

7. Fang H, Chen L, Knight JC. From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. *The Lancet Rheumatology* 2020; **2**(1): e50-e62.

8. Farrell SF, Campos AI, Kho PF, et al. Genetic basis to structural grey matter associations with chronic pain. *Brain* 2021; **144**(12): 3611–22.

9. Freidin MB, Tsepilov YA, Palmer M, et al. Insight into the genetic architecture of back pain and its risk factors from a study of 509,000 individuals. *PAIN* 2019; **160**(6): 1361-73.

10. Johnston KJA, Adams MJ, Nicholl BI, et al. Genome-wide association study of multisite chronic pain in UK Biobank. *PLoS Genet* 2019; **15**(6): e1008164.

11. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. *Br J Anaesth* 2019; **123**(2): e273-e83.

12. Roughan WH, Campos AI, García-Marín LM, et al. Comorbid Chronic Pain and Depression: Shared Risk Factors and Differential Antidepressant Effectiveness. *Front Psychiatry* 2021; **12**: 643609.

13. Cuéllar-Partida G, Lundberg M, Kho PF, et al. Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses. *bioRxiv* 2019: 518027.

14. Mbatchou J, Barnard L, Backman J, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nature genetics* 2021; **53**(7): 1097-103.

15. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. *Nature genetics* 2015; **47**(11): 1236-41.

16. Haworth S, Kho PF, Holgerson PL, et al. Assessment and visualization of phenome-wide causal relationships using genetic data: an application to dental caries and periodontitis. *European Journal of Human Genetics* 2021; **29**(2): 300-8.

17. O'Connor LJ, Price AL. Distinguishing genetic correlation from causation across 52 diseases and complex traits. *Nature genetics* 2018; **50**(12): 1728-34.

18. Meng W, Adams MJ, Reel P, et al. Genetic correlations between pain phenotypes and depression and neuroticism. *European Journal of Human Genetics* 2020; **28**(3): 358-66.

19. Diatchenko L, Fillingim RB, Smith SB, Maixner W. The phenotypic and genetic signatures of common musculoskeletal pain conditions. *Nature Reviews Rheumatology* 2013; **9**(6): 340-50.

20. Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. *Nat Rev Rheumatol* 2021; **17**(1): 59-66.

21. Sterling M, Smeets R, Keijzers G, Warren J, Kenardy J. Physiotherapist-delivered stress inoculation training integrated with exercise versus physiotherapy exercise alone for acute whiplash-associated disorder (StressModex): a randomised controlled trial of a combined psychological/physical intervention. *British Journal of Sports Medicine* 2019.

22. Elphinston RA, Sterling M, Kenardy J, Smeets R, Armfield NR. The mechanisms of effect of a physiotherapist-delivered integrated psychological and exercise intervention for acute whiplash-associated disorders: secondary mediation analysis of a randomized controlled trial. *Pain Rep* 2020; **5**(5): e835.

23. Sanchez-Roige S, Fontanillas P, Jennings MV, et al. Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. *Molecular Psychiatry* 2021.

24. Campos AI, Ngo TT, Medland SE, et al. Genetic risk for chronic pain is associated with lower antidepressant effectiveness: Converging evidence for a depression subtype. *Australian & New Zealand Journal of Psychiatry* 2021: 00048674211031491.

25. Ferreira GE, McLachlan AJ, Lin C-WC, et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. *BMJ* 2021; **372**: m4825.

26. Barowsky S, Jung J-Y, Nesbit N, et al. Cross-Disorder Genomics Data Analysis Elucidates a Shared Genetic Basis Between Major Depression and Osteoarthritis Pain. *Frontiers in Genetics* 2021; **12**(1276).

27. McLean SA, Ressler K, Koenen KC, et al. The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure. *Mol Psychiatry* 2020; **25**(2): 283-96.

28. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. *Genet Epidemiol* 2016; **40**(7): 597-608.

29. Rosoff DB, Smith GD, Lohoff FW. Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis. *JAMA Psychiatry* 2021; **78**(2): 151-60.

30. Brown MA, Xu H, Li Z. Genetics and the axial spondyloarthritis spectrum. *Rheumatology* 2020; **59**(Supplement_4): iv58-iv66.

Figures

Figure 1: Phenome-wide analysis pipeline for eight types of regional chronic pain with 1,492 other complex traits. Genome-wide association studies (GWAS) were performed for chronic back, neck/shoulder, hip, knee, abdominal, facial, headache and widespread pain. These results and publicly available GWAS summary statistics for 1,492 complex traits were uploaded into the Complex Traits Genetics Virtual Lab (CTG-VL), which along with CTG-VIEW was used to perform cross-trait linkage disequilibrium-score (LD-score) regression and latent causal variable analyses to respectively calculate genetic correlations (*rG*) and genetic causal proportions (GCP). The 570 traits with significant GCPs were categorised as per Figures 4–7 (x-axis) and Supplementary Tables S2–S9. This strategy enables the identification and targeting of genetically supported risk and protective factors for chronic pain types in further translationally focused studies.



Bivariate linkage disequilibrium score regression (FDR <5%)
— Genetic correlations (*rG*) between 8 chronic pain conditions & other complex traits (11,936 trait pairs) yielded 5,942 significant *rG*

Latent causal variable analyses (FDR <5%) of 5,942 *rG* yielded 570 traits pairs with significant genetic causal proportion (GCP)

GCP > 0.6 — chronic pain condition affects other trait

GCP < -0.6 — trait affects chronic pain condition

Figure 2: Scatterplot matrix showing the genetic correlations (*rG*) between chronic pain and 1,492 complex traits across the eight regional pain types. The genetic correlations were broadly consistent across these types, which indicates the genetic variants specific to each of the 1,492 complex traits had consistent correlations (positive or negative) with the genetic variants associated with each of the chronic pain types. This pattern of results points toward a shared genetic basis common to these chronic pain types, which may partly account for both an increased risk of developing chronic pain (more generally) and its commonly comorbid biopsychosocial traits.


Genetic Correlation (rG)
Back
Facial
Widespread
Headache
Hip
Knee
Neck or Shoulder
Abdominal
Genetic Correlation (rG)
Genetic Correlation (rG)

Figure 3: Scatterplot matrix showing 570 significant genetic causal proportions (GCPs) between chronic pain and 1,492 complex traits across the eight regional pain types wherein the LCV analysis method took into account the overlapping samples. There were eight instances where the direction of causal relationships (denoted by GCP > 0·6 or < -0·6) differed between the pain types as detailed in Supplementary Table S18. These included psychological traits (e.g., concerning mania/irritability), family history/social traits, musculoskeletal pathology and other clinical traits. Such differences in the traits' casual directions across pain types may reflect broader multi-directional dynamic relationships (e.g., mania/irritability both impacting & being affected by chronic pain) or may be more specific to regional pain types (e.g., arthrosis contributing to hip pain as joint pathology cf. abdominal pain contributing to arthrosis indirectly, such as via physical inactivity or another pathway). The otherwise broadly consistent direction of causal relationships with complex traits across these common chronic pain types supports a shared biopsychosocial genetic basis.


Genetic Causal Proportion (GCP)
Back
Facial
Widespread
Headache
Hip
Knee
Neck or Shoulder
Abdominal
−1.0
0.0
1.0

Figure 4: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of a causal effect upon regional chronic pain types (GCP < -0·6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic back pain, (**B**) neck/shoulder pain, (**C**) hip pain and (**D**) knee pain. A broad range of traits demonstrate evidence of genetic causal effects contributing to an increased risk of chronic pain — notably, psychological traits (e.g., depression on back, neck/shoulder, hip & knee pain), socioeconomic factors (e.g., work-related traits on back, neck/shoulder, hip & knee pain), musculoskeletal pathology (e.g., spondylopathies on neck/shoulder pain), medication use (e.g., dihydrocodeine on back pain) and addiction (e.g., smoking on back, neck/shoulder, hip & knee pain). Other traits had an apparent protective effect against these chronic pain types such as vegetable & dairy consumption and certain work-associated factors (e.g., software programmer/engineer and reduced risk of neck/shoulder pain — Supplementary Table S3 & Supplementary Results 2). BMI: body mass index; COPD: Chronic obstructive pulmonary disease.


A
Traits with Effects on Back Pain (GCP < -0.6)
N = 79,089 Cases
N = 239,125 Controls
PAIN
NO PAIN
rG
1.0
0.5
0.0
-0.5
-1.0
Smoking
Alcohol
Cardiovascular diseases
Toothache
Low density lipoprotein
No dairy
Eye related
Diseases of anus & rectum
Colitis
Respiratory haemorrhage
Hay fever rhinitis
Infectious & parasitic diseases
Medications
Metabolic disorders
Intervertebral disk disorders
Mania/irritability
Anxiety
Depression
Calf pain
Hysterectomy
Life-threatening illness
Menstruation issues
Work related
Sleep difficulty
Bladder disorders
Haematuria
Alcohol
Age started smoking
Folate
Calcium
Vegetables
Dementia (mother)
Work related
B
Traits with Effects on Neck/Shoulder Pain (GCP < -0.6)
N = 72,216 Cases
N = 239,125 Controls
PAIN
NO PAIN
Cannabis
Smoking
Alcohol
Glucosamine/chondroitin
Dental issues
Lung cancer
Chest pain
Ear/mastoid issues
Grandchild in household
Eye related
Diseases of anus & rectum
Iron deficient anaemia
Rheum arthritis
Medications
Spondylopathies
Dorsopathies
Hammer toe
Calf pain
Endometriosis
Mania
Anxiety
Alzheimers
Depression
Psychosis
COPD
Work related
Low density lipoprotein/ Apolipoprotein B
Vegetables
Child in household
Work related
C
Traits with Effects on Hip Pain (GCP < -0.6)
N = 41,677 Cases
N = 239,125 Controls
PAIN
NO PAIN
Cardiovascular diseases
Obesity
Glucose
BMI
Smoking
Cancers
Toothache
Non-butter spread
Cancer (sibling)
COPD (sibling)
Other type of coffee
Gastrointestinal diseases
Haematological
Menopause
Musculoskeletal (hip, spine, others)
Medications
Fibromyalgia
Mania/irritability
Anxiety
Bipolar
Depression
Calf pain
Alzheimers
Life-threatening illness
Metabolic disorders
Socioeconomic/ Work related
Plastic surgery
Sleep difficulty
Apolipoprotein B
High density lipoprotein/ Apolipoprotein A
Milk in tea
Vegetables
Breakfast cereals
Cognition
Child in household
Group social activities
Mother alive
Family history (various)
SPO2
Work related
D
Traits with Effects on Knee Pain (GCP < -0.6)
N = 77,996 Cases
N = 239,125 Controls
PAIN
NO PAIN
Alcohol
Smoking
Obesity
Apolipoprotein B
Hypertension
Dental
Other type of coffee
Low calorie
Nasal disorders
Bowel cancer (mother)
Living with relatives
Hernia
Rheum arthritis
Dyspepsia
Medications
Polyarthrosis
Spondylopathies
Intervertebral disk disorders
Depression
Psychosis
Bipolar
Anxiety
Socioeconomic/ Work related
Skin issues
Pneumonia, asthma/COPD
Work related
High density lipoprotein
No alcohol-related injuries
Milk in tea
Breakfast cereals
Vegetables
Age angina diagnosed
Addiction
Anthropometric
Blood Test
Cancer/Neoplasm
Cardiovascular
Dental
Diet
Ear Nose Throat
Education/Cognition
Eye
Family History
Family/Social
Gastrointestinal
Haematological
Hormones
Immune
Infectious
Medication
Metabolic
Miscellaneous
Musculoskeletal
Neurological
Pain
Psychological
Reproductive
Respiratory
Skin
Sleep
Socioeconomic
Surgical
Trauma/Injury/Stress
Urinary

Figure 5: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of a causal effect upon regional chronic pain types (GCP < -0·6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic abdominal pain, (**B**) facial pain, (**C**) headaches and (**D**) widespread pain. A broad range of traits demonstrate evidence of genetic causal effects on these pain types, including psychological (e.g., depression, trauma/stress, mania and/or anxiety on headaches, abdominal, facial & widespread pain), gastrointestinal (e.g., colitis on headaches & abdominal pain) and socioeconomic factors (e.g., work-related traits on headaches, abdominal, facial & widespread pain). Other traits had an apparent protective effect against certain chronic pain types such as dairy & cheese consumption (abdominal & widespread pain, respectively) and working as a teacher (abdominal & widespread pain). COPD: Chronic obstructive pulmonary disease; DVT: deep vein thrombosis; ECG: electrocardiogram; GGT: gamma-glutamyl transferase.


A
Traits with Effects on Abdominal Pain (GCP < -0.6)
N = 21,285 Cases
N = 239,125 Controls
PAIN
NO PAIN
rG
1.0
0.5
0.0
-0.5
-1.0
Substance/behaviour addiction
Smoking
Alcohol
Other type of coffee
No dairy
Cancers
Stroke
GGT
Syncope
Tinnitus
Leiomyoma
Memory test attempts
Diseases of anus & rectum
Colitis
Oesophagitis
Hernia
COPD (sibling)
Embolisms
H pylori
Cholelithiasis
Medications
Psoriasis
Metabolic disorders
Dorsalgia/back pain
Anxiety
Depression
Joint problem
Arm fracture
Breathing problems
Work related
Hysterectomy
Divorce
Death of a close relative
Renal calculi
High density lipoprotein/ Apolipoprotein A
Age started smoking
Reduced smoking for health
Age at first depression
No mania symptoms
Work related
B
Traits with Effects on Facial Pain (GCP < -0.6)
N = 4,037 Cases
N = 239,125 Controls
PAIN
NO PAIN
rG
1.0
0.5
0.0
-0.5
-1.0
Hypertension
Alcohol
Triglycerides
Sex hormone binding globulin (males)
Fibromyalgia
Mania/irritability
Psychosis
Unable to work due to sickness or disability
Sometimes worked with paints, thinners or glues
C
Traits with Effects on Headache (GCP < -0.6)
N = 39,283 Cases
N = 239,125 Controls
PAIN
NO PAIN
rG
1.0
0.5
0.0
-0.5
-1.0
Benign neoplasm bowel
Chest pain
Painful gums
Other type of coffee
Lung cancer (mother)
Adopted as a child
Hernia
Colitis
Pulmonary embolism
Dihydrocodeine
Dorsalgia
Intervertebral disk disorders
Arthrosis
Depression
Nervous feelings
Unable to work due to sickness or disability
COPD
Workplace hot
Rent home
Victim of sexual assault
Death of a close relative
Urinary disorders
D
Traits with Effects on Widespread Pain (GCP < -0.6)
N = 6,063 Cases
N = 239,125 Controls
PAIN
NO PAIN
rG
1.0
0.5
0.0
-0.5
-1.0
Smoking
Alcohol
Obesity
Stopped smoking
Alkaline phosphatase
Neoplasms
Cardiovascular issues
Triglycerides
Bilirubin
ECG load
Tinnitus
Living with relatives
Depression (mother)
Non-butter spread
Fruit
Starch
Cheese
Gastrointestinal diseases
Mother alive
Hypothyroidism/ myxoedema
DVT
Rheumatoid arthritis
Psoriasis
Intervertebral disk disorders
Medications
Endocrine, nutritional metabolic diseases
Back problem
Fracture
Osteoporosis
Chronic fatigue syndrome
Anxiety
Bipolar
Endometriosis
Mood disorders
Self-harm
Lost weight in depression episode
Asthma
Socioeconomic/ Work related
Plastic surgery
Sleep issues
Trauma
Work related
Addiction
Anthropometric
Blood Test
Cancer/Neoplasm
Cardiovascular
Dental
Diet
Ear Nose Throat
Education/Cognition
Eye
Family History
Family/Social
Gastrointestinal
Haematological
Hormones
Immune
Infectious
Medication
Metabolic
Miscellaneous
Musculoskeletal
Neurological
Pain
Psychological
Reproductive
Respiratory
Skin
Sleep
Socioeconomic
Surgical
Trauma/Injury/Stress
Urinary

Figure 6: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of being affected by chronic pain (GCP > 0·6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic back pain, (**B**) neck/shoulder pain, (**C**) hip pain and (**D**) knee pain. While there are fewer instances of these regional chronic pain affecting other traits than *vice versa* (Fig. 4), these results suggest these chronic pain types have genetic causal effects contributing to increased medication use (i.e., for cholesterol, blood pressure, diabetes or exogenous hormones) and an increased risk of cardiovascular disease (i.e., neck/shoulder pain on ischemic heart disease) along with other disorders (e.g., back pain on depression).


A
Traits Affected by Back Pain (GCP > 0.6)
N = 79,089 Cases
N = 239,125 Controls
PAIN
NO PAIN
rG
1.0
0.5
0.0
-0.5
-1.0
Arthrosis
Talking therapy for depression
No medications for cholesterol, blood pressure, diabetes, or exogenous hormones
Nil trauma/stress in prior 2 years
B
Traits Affected by Neck/Shoulder Pain (GCP > 0.6)
N = 72,216 Cases
N = 239,125 Controls
Infectious & parasitic diseases
Other specific/ unspecified arthritis
Ischaemic heart disease
No cardiovascular disease
No medications for cholesterol, blood pressure, diabetes, or exogenous hormones
C
Traits Affected by Hip Pain (GCP > 0.6)
N = 41,677 Cases
N = 239,125 Controls
No medications for cholesterol, blood pressure, diabetes, or exogenous hormones
D
Traits Affected by Knee Pain (GCP > 0.6)
N = 77,996 Cases
N = 239,125 Controls
Chronic neck/ shoulder pain
No medications for cholesterol, blood pressure, diabetes, or exogenous hormones
Addiction
Anthropometric
Blood Test
Cancer/Neoplasm
Cardiovascular
Dental
Diet
Ear Nose Throat
Education/Cognition
Eye
Family History
Family/Social
Gastrointestinal
Haematological
Hormones
Immune
Infectious
Medication
Metabolic
Miscellaneous
Musculoskeletal
Neurological
Pain
Psychological
Reproductive
Respiratory
Skin
Sleep
Socioeconomic
Surgical
Trauma/Injury/Stress
Urinary

Figure 7: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of being affected by chronic pain (GCP > 0·6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic abdominal pain, (**B**) facial pain, (**C**) headaches and (**D**) widespread pain. Notably, facial pain showed effects on a wide range of traits including dietary patterns (e.g., reduced muesli, ground coffee), psychological factors (e.g., increased depression, anxiety) and an increased risk of neurological conditions (e.g., mononeuropathies, carpal tunnel syndrome), whereas abdominal pain particularly contributed to an increased risk of cardiovascular disease (e.g., hypertension). Chronic headache had genetic effects contributing to increased analgesic use (i.e., paracetamol, ibuprofen, aspirin) & psychological traits (e.g., depression). Widespread pain affected a range of traits such as an increased risk of surgical complications, analgesic use and disability parking permit use. ECG: electrocardiogram.


A
Traits Affected by Abdominal Pain (GCP > 0.6)
N = 21,285 Cases
N = 239,125 Controls
PAIN
NO PAIN
rG
1.0
0.5
0.0
-0.5
-1.0
Chest pain during physical activity
Hypertension
Cardiovascular disease (sibling)
Infectious & parasitic diseases
Hip pain in last month
Sleep change in context of depression
Blood pressure medication
Arthrosis
Coronary artery disease
No cardiovascular disease
Stopped smoking as health precaution
No medications for cholesterol, blood pressure, diabetes, or exogenous hormones
B
Traits Affected by Facial Pain (GCP > 0.6)
N = 4,037 Cases
N = 239,125 Controls
PAIN
NO PAIN
Signal-to-noise-ratio of triplet (right) (hearing test)
Vocational qualification
Respiratory haemorrhage
Infectious & parasitic diseases
Neurological diseases
Anxiety
Mania/ irritability
Blue Badge parking permit
Leg fat percentage
Ischaemic heart disease
High cholesterol
Hormone-replacement therapy
Nerve, nerve root & plexus disorders
Depression
Mononeuropathies
Carpal tunnel syndrome
Serious illness, injury or assault
Dozing
Ground coffee
Eggs, dairy, wheat, sugar
Muesli
No major dietary changes in the last 5 years
Cycle
Workplace rarely/ never very cold
C
Traits Affected by Headache (GCP > 0.6)
N = 39,283 Cases
N = 239,125 Controls
PAIN
NO PAIN
Headache
Paracetamol
Multisite chronic pain
Ibuprofen
Speech-reception-threshold estimate (right) (hearing test)
Depression
Mania/irritability
Facial pain
Aspirin
Talking therapy for depression
No bipolar or depression
No medications for pain relief, constipation, heartburn
Nil pain in last month
D
Traits Affected by Widespread Pain (GCP > 0.6)
N = 6,063 Cases
N = 239,125 Controls
PAIN
NO PAIN
Workplace sometimes dusty
Grandchild in household
Chronic neck/shoulder pain
Other arthrosis
Duration of vigorous activity
Paracetamol
Pain in throat and chest
Surgical complications
Blue Badge parking permit
Dementia (mother)
Exercise ECG test traits
Addiction
Anthropometric
Blood Test
Cancer/Neoplasm
Cardiovascular
Dental
Diet
Ear Nose Throat
Education/Cognition
Eye
Family History
Family/Social
Gastrointestinal
Haematological
Hormones
Immune
Infectious
Medication
Metabolic
Miscellaneous
Musculoskeletal
Neurological
Pain
Psychological
Reproductive
Respiratory
Skin
Sleep
Socioeconomic
Surgical
Trauma/Injury/Stress
Urinary

Figure 8: Causal architecture plots presenting the relationships of various traits with (**A**) chronic back pain, (**B**) neck/shoulder pain and (**C**) hip pain. Each dot represents a genetic correlation (*rG*). The colour of a dot indicates whether the genetic correlation is positive (red) or negative (blue). The x-axis denotes the genetic causal proportion (GCP) estimate and the y-axis denotes the GCP absolute Z-score (i.e., statistical significance). The red dashed line shows the threshold for statistical significance (5% false discovery rate). Traits that have a genetic causal effect on chronic pain are on the left side of the plot (with respect to 0 on the x-axis, GCP < -0·6, black text), while traits causally affected by chronic pain are on the right side (GCP > 0·6, green text). Selected traits are labelled for illustrative purposes — spanning clinical, biological, psychological and socioeconomic measures. Full details of all significant genetic causal relationships are provided in Supplementary Tables S2, S3 & S4. Causal architecture plots for the other regional chronic pain types are presented in Supplementary Figures S1 & S2.


A
Chronic Back Pain
Job SOC coding: Receptionists
Trouble falling asleep
Job coding: Assembler, machine operator, foreman
Never eat: Dairy products
Diagnoses - main ICD10: I10 Essential (primary hypertension)
Ever had a period of mania/excitability
Diagnoses - main ICD10: M51 Other intervertebral disk disorders
Diagnoses - main ICD10: K62 Other diseases of anus and rectum
Treatment/medication code: Dihydrocodeine
Diagnoses - main ICD10: M19 Other arthrosis
Strength of evidence for partial genetic causality (|Z|)
Estimated magnitude of partial genetic causality (GCP)


B
Chronic Neck or Shoulder Pain
How are people in household related to participant: Grandchild
Treatment/medication code: Glyceryl trinitrate (GTN) 400 mg spray
Other hammer toe(s) (acquired)
Apolipoprotein B (quantile) both sexes
Spondylopathies
Job SOC coding: Elementary office occupations
Substances taken for anxiety: Drugs or alcohol
Age when last took cannabis
Pneumonias
Treatment/medication code: Atenolol
Coronary atherosclerosis
Strength of evidence for partial genetic causality (|Z|)
Estimated magnitude of partial genetic causality (GCP)


C
Chronic Hip Pain
Stroke
Severity of problems due to mania or irritability
Fibromyalgia related co-morbidities
Illnesses of siblings: Bowel cancer
Job coding: Scientific researcher, scientific officer
Treatment/medication code: Ipratropium
Alzheimers
Diagnoses - main ICD10: M16 Coxarthrosis [arthrosis of hip]
Glucose (quantile) male
Vegetable consumers
Professional informed about anxiety
Obesity
Substances taken for anxiety: Drugs or alcohol
Age stopped smoking
Probable Recurrent major depression (moderate)
Medication for cholesterol, blood pressure, diabetes, exogenous hormones: None of the above
Strength of evidence for partial genetic causality (|Z|)
Estimated magnitude of partial genetic causality (GCP)
-1
rG
1